GuillaumeMonnier

Associate

Paris + 33.1.56.59.39.40

Connect:

Share

Guillaume Monnier advises issuers and underwriters in debt and equity capital markets transactions. His experience includes initial public offerings (IPOs), capital increases, block trades, stand-alone issues, convertible and exchangeable bonds, liabilities management, and debt securities under euro medium-term note (EMTN) programs.

Since joining Jones Day in 2020, Guillaume has advised issuers and bank syndicates on capital market transactions involving Carbios, MedinCell, OSE Immunotherapeutics (capital increases), Alchimie (IPO), Voltalia (convertible bonds), Bigben Interactive (exchangeable bonds), Bombardier, and SC de l'Ermitage Saint Joseph (block trades).

Guillaume practiced at an international law firm in Paris prior to joining Jones Day.

Experience

  • Underwriters complete €114 million capital increase of CarbiosJones Day represented the underwriters in connection with a capital increase of Carbios, a green chemistry company, of €114 million.
  • Bombardier sells entire stake in Alstom for €506 millionJones Day acted as French corporate and capital markets counsel to Bombardier Inc., a leading manufacturer of business jets, in the sale of its entire stake in Alstom S.A. for an amount of €506 million in an accelerated bookbuilt offering to qualified investors.
  • EDAP completes follow-on offering of American Depositary SharesJones Day represented EDAP TMS, a global leader in robotic energy-based therapies, in connection with its follow-on offering of 4,150,000 American Depositary Shares (ADSs) on the Nasdaq Global Market.
  • Berenberg, BNP Paribas, and TP ICAP Europe complete €87.3 million offering by Bigben Interactive of its inaugural senior conditionally secured bonds exchangeable into existing ordinary shares of NaconJones Day advised Berenberg, BNP Paribas, and TP ICAP Europe, as joint global coordinators and joint bookrunners, in connection with a €87.3 million offering by Bigben Interactive, a European player in video game development and publishing, in design and distribution of smartphone and gaming accessories as well as in audio products, of its inaugural senior conditionally secured bonds exchangeable into existing ordinary shares of Nacon due 2026.
  • SC de l’Ermitage Saint Joseph sells its interest in Pharmagest InteractiveJones Day represented SC de l’Ermitage Saint Joseph, a French société civile held by the founder and Chairman of the Board of Directors of Pharmagest, in the €73.6 million sale of all its shares in Pharmagest Interactive.
  • Bryan, Garnier & Co Limited and ODDO BHF SCA complete €29.8 million capital increase of MedinCell S.A.Jones Day represented Bryan, Garnier & Co Limited (acting via Bryan Garnier Securities SAS) and ODDO BHF SCA, as joint global coordinators and joint bookrunners, in connection with the €29.8 million capital increase of MedinCell S.A., a clinical stage pharmaceutical company.
  • Voltalia issues inaugural green bondsJones Day represented Voltalia in connection with its inaugural green bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs Vertes) due 2025 for a nominal amount of approximately €200 million as well as within the implementation of its Green & Sustainability-linked Financing Framework.
  • Alchimie completes €17.9 million IPO of Ordinary SharesJones Day advised Alchimie SAS, a French OTT subscription video on demand platform, in connection with the €17.9 million initial public offering of Ordinary Shares listed on the multilateral trading facility of Euronext Growth Paris.
  • Bank Degroof Petercam SA/NV and Invest Securities complete €18.6 million private placement of shares by OSE Immunotherapeutics S.A.Jones Day represented Bank Degroof Petercam SA/NV and Invest Securities SA in connection with the €18.6 million private placement of shares by OSE Immunotherapeutics S.A., a French integrated biotechnology company developing innovative immunotherapies, directly or through partnerships, for immune activation and regulation in immuno-oncology and autoimmune diseases.
  • Natixis, ODDO BHF SCA, and Bryan, Garnier & Co Limited complete €37 million private placement of shares by CarbiosJones Day represented Natixis, ODDO BHF SCA, and Bryan, Garnier & Co Limited, as joint global coordinators, joint lead managers, and joint bookrunners, in connection with the €37 million private placement of shares of Carbios, a French green chemistry company.
  • Oddo BHF SCA and Bryan, Garnier & Co Limited complete €15.6 million share capital increase of MedinCell S.A.Jones Day advised Oddo BHF SCA and Bryan, Garnier & Co Limited, as placement agents, in connection with the €15.6 million share capital increase of MedinCell S.A., a clinical stage pharmaceutical company.
    • View All
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.